

Burden of Illness of Lupus Nephritis in Patients With Systemic Lupus Erythematosus

Poster number: PO1768

Christopher F Bell¹, Benjamin Wu^{1*}, Bin Xie², Shirley Huang¹, Benjamin Chastek², Bernie Rubin³, Joan Von Feldt^{3*,4}, Gary Bryant^{3*}

¹GlaxoSmithKline, Research Triangle Park, NC, USA; ²Optum, Eden Prairie, MN, USA; ³GlaxoSmithKline, Philadelphia, PA, USA; ⁴University of Pennsylvania, Philadelphia, PA, USA

*At the time of the study

Conclusions

In a real-world setting in the USA, all-cause HRU and healthcare costs were significantly higher for patients with LN than those without SLE and renal impairment, highlighting the substantial economic burden of LN


Introduction

LN is a serious complication of SLE and is developed by approximately 40% of patients with SLE^{1,2}. LN is a major risk factor for renal failure, morbidity, and mortality in patients with SLE². Little is known about HRU or costs of care for patients with LN. This is a retrospective observational cohort study (GSK Study 213062) to identify the burden of LN among patients managed in routine clinical practices in the USA.

Objective




To compare HRU and costs of care of patients with LN with matched controls with no evidence of SLE and renal impairment

Methods



Results

| | LN (N=2,326) | Control (N=2,326) |
|-----------------------|--------------------|--------------------|
| Mean (SD) age | 60.1 (15.42) years | 60.1 (15.42) years |
| Age group | | |
| 18–44 years | 17.4% (n=405) | 17.4% (n=405) |
| 45–64 years | 38.5% (n=896) | 38.5% (n=896) |
| 65+ years | 44.1% (n=1,025) | 44.1% (n=1,025) |
| Female | 85.6% (n=1,991) | 85.6% (n=1,991) |
| Region | | |
| Northeast | 8.3% (n=193) | 8.3% (n=193) |
| Midwest | 22.2% (n=517) | 22.2% (n=517) |
| South | 58.1% (n=1,351) | 58.1% (n=1,351) |
| West | 11.3% (n=264) | 11.3% (n=264) |
| Other | 0.04% (n=1) | 0.04% (n=1) |
| Insurance type | | |
| Commercial | 33.7% (n=784) | 33.7% (n=784) |
| Medicare | 66.3% (n=1,542) | 66.3% (n=1,542) |



Limitations

Administrative claims data are subject to a number of limitations, including (but not limited to): data coding error/mis-specification, data entry error, and lack of patient-centric measures (eg, SELENA-SLEDAI, quality of life). The study population included patients with commercial and Medicare Advantage insurance coverage, as such study results may not be generalizable (eg, mean age of population was ~60 years).

Abbreviations

HRU, healthcare resource utilization; LN, lupus nephritis; SD, standard deviation; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index; SLE, systemic lupus erythematosus; USA, United States of America; USD, United States Dollar.

References

1. Mohan C and Putterman C. *Nat Rev Nephrol.* 2015;11:329–341.
2. Hanly JG, et al. *Rheumatology.* 2016;55:252–262.

Acknowledgments

This work was funded by GlaxoSmithKline (GSK Study 213062). Medical writing support was provided by Casmira Brazaitis, PhD, of Fishawack Indicia Ltd, UK, and was funded by GSK.

Disclosures

CFB, SH and BR are employees of GSK and hold stocks and shares in the company. BW, JVF and GB are former employees of GSK and hold stocks and shares in the company. BX and BC are employees of Optum.

Please find the online version of this poster by scanning the Quick Response (QR) code or via tago.ca/asn2

Copies of this poster obtained through QR Code are for personal use only and may not be reproduced without permission from ASN and the authors of this poster.

